# Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

> **NCT00061308** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 75 (—)

## Conditions studied

- Peritoneal Cancer
- Ovarian Cancer
- Neoplasms, Ovarian
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00061308
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** 75 (—)
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061308, "Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00061308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*